$7.50
1.21% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Enanta Pharmaceuticals, Inc. Stock price

$7.50
+2.27 43.40% 1M
+1.47 24.38% 6M
+1.75 30.43% YTD
-5.93 44.15% 1Y
-42.54 85.01% 5Y
-35.71 82.64% 10Y
-9.68 56.34% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
+0.09 1.21%
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Key metrics

Market capitalization $160.32m
Enterprise Value $-31.71m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.39
EV/Sales (TTM) EV/Sales -0.49
P/S ratio (TTM) P/S ratio 2.49
P/B ratio (TTM) P/B ratio 1.71
Revenue growth (TTM) Revenue growth -11.55%
Revenue (TTM) Revenue $64.46m
EBIT (operating result TTM) EBIT $-102.11m
Free Cash Flow (TTM) Free Cash Flow $-82.24m
Cash position $193.38m
EPS (TTM) EPS $-4.51
P/E forward negative
P/S forward 2.56
EV/Sales forward negative
Short interest 13.53%
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

3x Buy
60%
1x Hold
20%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
60%
Hold
20%
Sell
20%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
64 64
12% 12%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 51 51
10% 10%
80%
- Research and Development Expense 115 115
24% 24%
179%
-99 -99
26% 26%
-153%
- Depreciation and Amortization 3.17 3.17
23% 23%
5%
EBIT (Operating Income) EBIT -102 -102
25% 25%
-158%
Net Profit -96 -96
27% 27%
-150%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
3 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for MAVYRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct acting antiviral (DAA)...
Neutral
Business Wire
18 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025...
Neutral
Business Wire
23 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd An...
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 131
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today